Zacks: Atrion Co. (ATRI) Given Average Recommendation of “Strong Sell” by Analysts
Atrion Co. (NASDAQ:ATRI) has received a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that provide coverage for the stock, Zacks Investment Research reports.
Zacks has also given Atrion an industry rank of 74 out of 255 based on the ratings given to related companies.
Several brokerages have recently issued reports on ATRI. BidaskClub upgraded Atrion from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 27th. ValuEngine upgraded Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th.
Shares of Atrion stock opened at $920.05 on Monday. The stock has a market cap of $1.72 billion, a PE ratio of 50.41 and a beta of 0.44. Atrion has a 52-week low of $560.65 and a 52-week high of $948.03.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were paid a $1.35 dividend. This represents a $5.40 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date was Thursday, March 14th.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Story: Backdoor Roth IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.